FSGS in Practice: Patient-Centered Decision-Making

ReachMD Healthcare Image
Media formats available:
Details
Presenters
  • Overview

    Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the disease progresses. However, the current absence of FDA-approved treatments tailored specifically for treating adult and pediatric patients with FSGS poses a significant challenge to effectively managing this disease. Moreover, it is imperative for nephrologists to enhance their skills to implement practical strategies that improve the diagnostic approach for suspected FSGS cases, especially considering the profound impact of FSGS on patients' quality of life. This activity has been designed to provide practical guidance for the accurate diagnosis of FSGS and appropriate  treatment selection, as well as to offer an expert assessment of the clinical trial data supporting emerging therapies in this setting. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Kenneth Lieberman, MD
    Chief, Pediatric Nephrology
    Joseph M. Sanzari Children's Hospital
    Hackensack University Medical Center
    Hackensack, NJ

    Dr. Lieberman has no relevant relationships to disclose.

    Howard Trachtman, MD, FASN
    Adjunct Professor of Pediatrics
    University of Michigan
    Ann Arbor, MI

    Dr. Trachtman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Advisor/Consultant: Aclipse, Alexion, Eloxx, Boehringer-Ingelheim, Dimerix, Maze Therapeutics, NephCure, Otsuka, PhaseV, Travere Therapeutics, Walden, ProKidney, Novartis, Vera Therapeutics
    Shareholder: Aclipse

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose.
    • Wilma Guerra has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAFFP, has no relevant relationships to disclose. 
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Apply practical strategies to enhance the diagnostic approach for adult and pediatric patients suspected of having focal segmental glomerulosclerosis (FSGS)
    • Select appropriate treatment targets for adult and pediatric patients with FSGS based on patient characteristics
    • Assess the evidence-based effects of emerging treatments on health-related quality of life metrics in adult and pediatric patients with FSGS
  • Target Audience

    This activity has been designed to meet the educational needs of nephrologists and nurses as well as all other physicians, physician assistants, nurse practitioners, pharmacists, and healthcare providers involved in managing patients with focal segmental glomerulosclerosis (FSGS).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hour(s)/0.025 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-0000-25-074-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credit(s). Approval is valid until June 2, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Travere Therapeutics, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 

    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Medtelligence…
but how about a more personalized experience?

Register for free